• The GDG considered in vitro data demonstrating that neutralization of currently circulating variants of SARS-CoV-2 and their subvariants with sotrovimab is diminished.
• There was consensus among the panel that the meaningful reduction of in vitro neutralization activity strongly suggests absence of clinical effectiveness of monoclonal antibodies such as sotrovimab.
• There was also consensus regarding the need for clinical trial evidence in order to confirm clinical effectiveness of new monoclonal antibodies that reliably neutralize circulating strains in vitro.

Practical info Given the strong recommendation against using sotrovimab for patients with non-severe COVID-19, practical considerations were felt to be less relevant here.